Beyond today’s treatments for serious cardiovascular disease, we believe the future may lie in developing biotherapeutic approaches that use gene therapy to trigger angiogenesis – the growth of new blood vessels in diseased hearts. 

With that in mind, Edwards has formed a relationship with Sangamo BioSciences Inc., exclusively licensing their growth-factor regula- tion technology for cardiovascular applications. While this work is highly experimental, new blood vessels – possibly created through the application of this technology – could restore blood flow for patients suffering from coronary artery and peripheral vascular disease. This early stage research combines Sangamo’s gene therapy technology with Edwards’ expertise in catheter-based delivery systems to pursue novel cardiovascular biotherapeutics. 

## EXPLORING ANGIOGENESIS 

Beyond pursuing what may be the next breakthroughs in cardiovascular disease treatment, Edwards is committed to building on our leading products and technologies to meet the evolving needs of patients and clinicians worldwide. We continue to increase our internal research and development investments to expand our core heart valve therapy, critical care and vascular franchises by developing newer, more effective and less-invasive therapies. 

Already the number-one heart valve replacement and repair company in the world, we are looking to expand our product portfolio with next-generation pericardial tissue valves and enhanced tissue processing technologies. We are exploring new developments that could one day make the dream of minimally invasive valve repair and percutaneous valve replacement a reality. And these are just a few examples of the unmet clinical opportunities that exist as we forge ahead to extend our legacy of innovation – and to realize our aspirations as a company transformed. 

## EXPANDING OUR CORE TECHNOLOGIES 

